Clinical Trial Update: VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of Velcade (bortezomib) in mucosa-associated lymphoid tissue lymphoma pretreated with multiple prior systemic therapies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosa-associated Lymphoid Tissue Lymphoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Conditions: Lymphoma, Mucosa-Associated Lymphoid Tissue | Phase 2 | Status: TERMINATED